Product Images Aripiprazole

This is a medication packaging of ARIPiprazole, 5mg tablets, with a quantity of 30, packaged by RemedyRepack Inc. The medication is manufactured by Amneal Pharma in Ahmedabad, India. The packaging includes RX only, NDC and LOT numbers, and a warning to keep it out of reach of children. It also includes directions on usage and storage temperature.*

This is a medication called ARIPiprazole, which comes in a tablet form of 5mg. The medication is available in a package of 1 tablet. The medication has been repackaged by RemedyRepack Ine. The manufacturer of the medication is Amneal Pharma, located in Ahmedabad, India 382220. The directions for use of the medication can be found in the package insert. The medication should be stored at a temperature between 20-25°C (88-77°F), with excursions permitted between 15-30°C (59-86°F) [See USP]. The NDC number for the medication is 70518-0970-02, and the LOT number and expiration date are not available. This medication is available only with a prescription (Rx only) and should be kept out of the reach of children.*

This is a medication packaging of Aripiprazole tablets with a strength of 5mg. The packet contains 30 tablets and has been repackaged by RemedyRepack. The medication is manufactured by Amneal Pharma in Ahmedabad, India. The medication should be kept away from children and should be stored at 20-25°C (88-77°F) with excursions permitted to 15-30°C (59-86°F). The package insert should be referred to for direction on usage. The expiration date and Lot number are not available in the text.*

The text seems to be a table listing the effect of Aripiprazole on other drugs. It includes drug names such as dextromethorphan, warfarin, omeprazole, valproate, lithium, lorazepam, escitalopram, and others. There are some acronyms such as CYP2D6 and UGT1A4 present in the table. The data seems to include fold change and 90% I. However, the table is not legible, so a useful description cannot be provided.*

The text refers to a table about special populations in the context of PK (pharmacokinetics) and Avipiprazole, a medication used to treat mental/mood disorders. The table includes different variables such as poor vs. extensive metabolizer, gender (female vs. male), age (18-64 vs. 65 years old and older), and hepatic/renal impairments. The last section of the table shows the Avipiprazole fold change and 90% CI (confidence interval).*

This appears to be a graph displaying a comparison between Avipiprazole and Placebo in relation to Proportion with Relapse. The x-axis appears to represent "Days from Randomization" with ticks every 14 days, whereas the y-axis represents "Proportion with Relapse". There are two lines, one for Avipiprazole and one for Placebo, with dots on the lines indicating the values for each day. However, without more context or a clearer image, it is difficult to provide more details.*

The text describes a graph comparing the proportions of subjects with relapse between Aripiprazole and Placebo groups over time, measured in days from Randomization. The graph shows data points for each group at different time intervals, and the number of subjects at risk for each group at each interval.*